Cargando…

Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus

Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Qiuxia, Wang, Yan, Jin, TaiCheng, Zhu, Lei, Wu, XianYan, Li, YiKun, Wang, YanJiao, Xu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280620/
https://www.ncbi.nlm.nih.gov/pubmed/35846273
http://dx.doi.org/10.3389/fendo.2022.892127
_version_ 1784746688103055360
author Min, Qiuxia
Wang, Yan
Jin, TaiCheng
Zhu, Lei
Wu, XianYan
Li, YiKun
Wang, YanJiao
Xu, Ning
author_facet Min, Qiuxia
Wang, Yan
Jin, TaiCheng
Zhu, Lei
Wu, XianYan
Li, YiKun
Wang, YanJiao
Xu, Ning
author_sort Min, Qiuxia
collection PubMed
description Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, the regulatory role of probiotics on intestinal metabolites after treatment of type 2 diabetes mellitus remains unclear. The purpose of this study was to investigate the therapeutic effect of probiotics on type 2 diabetes mellitus and its regulatory effect on short-chain fatty acids, which are metabolites of intestinal microorganisms. I collected feces from 15 patients with diabetes before treatment and 15 patients with type 2 diabetes after treatment with GLP-1 and probiotics. The abundance of short-chain fatty acids in feces was determined by GC-MS. Results Both GLP-1 and probiotics could improve the levels of blood glucose, urine glucose and BMI in patients with type 2 diabetes. After glP-1 treatment, two short-chain fatty acids (butyric acid and valerate acid) in intestine were significantly changed. Propionic acid and isovalerate were significantly changed after probiotic treatment. At the same time, KEGG signal pathway enrichment results showed that probiotics intervention mainly achieved the purpose of treating type 2 diabetes through regulating protein and carbohydrate metabolism. Taken together, our study shows changes in intestinal short-chain fatty acids after probiotics or GLP-1 treatment of type 2 diabetes, which will provide us with new insights into the mechanism of probiotics treatment of type 2 diabetes, as well as potential intervention targets for diabetes treatment.
format Online
Article
Text
id pubmed-9280620
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92806202022-07-15 Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus Min, Qiuxia Wang, Yan Jin, TaiCheng Zhu, Lei Wu, XianYan Li, YiKun Wang, YanJiao Xu, Ning Front Endocrinol (Lausanne) Endocrinology Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, the regulatory role of probiotics on intestinal metabolites after treatment of type 2 diabetes mellitus remains unclear. The purpose of this study was to investigate the therapeutic effect of probiotics on type 2 diabetes mellitus and its regulatory effect on short-chain fatty acids, which are metabolites of intestinal microorganisms. I collected feces from 15 patients with diabetes before treatment and 15 patients with type 2 diabetes after treatment with GLP-1 and probiotics. The abundance of short-chain fatty acids in feces was determined by GC-MS. Results Both GLP-1 and probiotics could improve the levels of blood glucose, urine glucose and BMI in patients with type 2 diabetes. After glP-1 treatment, two short-chain fatty acids (butyric acid and valerate acid) in intestine were significantly changed. Propionic acid and isovalerate were significantly changed after probiotic treatment. At the same time, KEGG signal pathway enrichment results showed that probiotics intervention mainly achieved the purpose of treating type 2 diabetes through regulating protein and carbohydrate metabolism. Taken together, our study shows changes in intestinal short-chain fatty acids after probiotics or GLP-1 treatment of type 2 diabetes, which will provide us with new insights into the mechanism of probiotics treatment of type 2 diabetes, as well as potential intervention targets for diabetes treatment. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9280620/ /pubmed/35846273 http://dx.doi.org/10.3389/fendo.2022.892127 Text en Copyright © 2022 Min, Wang, Jin, Zhu, Wu, Li, Wang and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Min, Qiuxia
Wang, Yan
Jin, TaiCheng
Zhu, Lei
Wu, XianYan
Li, YiKun
Wang, YanJiao
Xu, Ning
Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title_full Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title_fullStr Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title_full_unstemmed Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title_short Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
title_sort analysis of intestinal short-chain fatty acid metabolism profile after probiotics and glp-1 treatment for type 2 diabetes mellitus
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280620/
https://www.ncbi.nlm.nih.gov/pubmed/35846273
http://dx.doi.org/10.3389/fendo.2022.892127
work_keys_str_mv AT minqiuxia analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT wangyan analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT jintaicheng analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT zhulei analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT wuxianyan analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT liyikun analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT wangyanjiao analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus
AT xuning analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus